AAP
PVLA

Arax Advisory Partners’s Palvella Therapeutics PVLA Stock Holding History

Arax Advisory Partners’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.9K Buy
+19
New +$2.31K ﹤0.01% 4724
2025
Q4 		– Sell
-91
Closed -$5.7K – 4615
2025
Q3 		$5.7K Buy
+91
New +$4.06K ﹤0.01% 2832

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Arax Advisory Partners's PVLA Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Palvella Therapeutics (PVLA) in Q2 2026: 19 shares worth $2.9K. The stake represents ﹤0.01% of the portfolio and ranks #4724 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in PVLA as recently as Q3 2025.

Arax Advisory Partners first reported a position in PVLA in Q3 2025 and has held it in 2 quarters since. The position peaked at $5.7K in Q3 2025. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Arax Advisory Partners held 19 shares of Palvella Therapeutics worth $2.9K as of Q2 2026.
  • Palvella Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Palvella Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4724 holding.
  • Arax Advisory Partners first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Arax Advisory Partners's Palvella Therapeutics position peaked at $5.7K in Q3 2025.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.